Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

Canadá - inglês - Health Canada

fresenius kabi canada ltd - morphine sulfate - solution - 2mg - morphine sulfate 2mg - opiate agonists

Canadá - inglês - Health Canada

fresenius kabi canada ltd - morphine sulfate - solution - 4mg - morphine sulfate 4mg - opiate agonists

Canadá - inglês - Health Canada

fresenius kabi canada ltd - morphine sulfate - solution - 5mg - morphine sulfate 5mg - opiate agonists

Canadá - inglês - Health Canada

fresenius kabi canada ltd - morphine sulfate - solution - 8mg - morphine sulfate 8mg - opiate agonists

Canadá - inglês - Health Canada

fresenius kabi canada ltd - morphine sulfate - solution - 10mg - morphine sulfate 10mg - opiate agonists

Estados Unidos - inglês - NLM (National Library of Medicine)

stat rx usa llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride tablets, usp are indicated for the management of pain in patients where an opioid analgesic is appropriate. hydromorphone hydrochloride tablets are contraindicated in: patients with known hypersensitivity to hydromorphone, patients with respiratory depression in the absence of resuscitative equipment, and in patients with status asthmaticus. hydromorphone hydrochloride tablets are also contraindicated for use in obstetrical analgesia. hydromorphone hydrochloride tablets contain hydromorphone, a schedule ii controlled opioid agonist. schedule ii opioid substances which include morphine, oxycodone, oxymorphone, fentanyl, and methadone have the highest potential for abuse and risk of fatal overdose. hydromorphone can be abused and is subject to criminal diversion. opioid analgesics may cause psychological and physical dependence. physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug. physical dependence usually does not occur to a

Estados Unidos - inglês - NLM (National Library of Medicine)

cardinal health - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - in anesthesia: glycopyrrolate injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. when indicated, glycopyrrolate injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. in peptic ulcer: for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. known hypersensitivity to glycopyrrolate or any of its inactive ingredients. in addition, in the management of peptic ul